سعر لوتيميب 10مجم 10قرص 2022

Ezetimibe 10 mg tablets (Pharopharma, Egypt); intestinal cholesterol absorption inhibitor.

• With a statin, or alone when additional LDL-C lowering therapy is not possible, as adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia including HeFHPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• With a statin in pediatric patients 10 years and older with HeFH; with fenofibrate in adults with mixed hyperlipidemia; in HoFH with other LDL-C lowering therapies; homozygous sitosterolemiaPopulation: Adults and children >= 10 yearsDailyMed (U.S. National Library of Medicine)

• Monotherapy (>= 2% and above placebo): upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue and influenza.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to ezetimibe or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• When combined with a statin, fenofibrate or other LDL-C lowering therapy, contraindicated in patients for whom that therapy is contraindicated.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Increases in serum transaminases reported; perform liver enzyme testing as clinically indicated and consider withdrawal if ALT or AST >= 3 x ULN persist.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• May cause myopathy and rhabdomyolysis; discontinue if myopathy is suspected or CK markedly elevated.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CyclosporineIncreases ezetimibe and cyclosporine concentrations; monitor cyclosporine levels.DailyMed (U.S. National Library of Medicine)
• FibratesFenofibrate and ezetimibe may increase cholelithiasis risk; co-administration with fibrates other than fenofibrate is not recommended.DailyMed (U.S. National Library of Medicine)
• Bile acid sequestrants (cholestyramine)Decrease ezetimibe exposure; separate administration (>= 2 h before or >= 4 h after).DailyMed (U.S. National Library of Medicine)

• Insufficient data in pregnant women to evaluate drug-associated risk; no adverse developmental effects in pregnant rats at the studied exposures.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk (present in rat milk); the label advises against use in nursing mothers unless the benefit justifies the potential risk to the infant.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ezetimibe: Inhibits intestinal absorption of cholesterol and phytosterols by targeting the sterol transporter NPC1L1 at the brush border of the small intestine.